Type 1 Diabetes Clinical Trial
Official title:
Determining the Appropriate Intensity of Vigorous Intensity Exercise to Prevent Post-exercise Hypoglycemia in Persons Living With Type 1 Diabetes
NCT number | NCT03583268 |
Other study ID # | B2014:095 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2013 |
Est. completion date | March 2016 |
Verified date | June 2018 |
Source | University of Manitoba |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Over 300, 000 youth and young adults across Canada are living with Type 1 Diabetes (T1D)
which is considered the most common endocrine condition. Physical activity offers numerous
health benefits however the majority of persons living with T1D are physically inactive,
primarily due to fear of low blood sugar (hypoglycemia). This fear of hypoglycemia continues
to exist for physically active persons with T1D as no established physical activity
guidelines exist. Several acute studies have used high intensity interval training as a way
to reduce the risk of hypoglycemia as it has the ability to activate fight or flight hormones
which can raise blood sugar; however the intensity needed to elicit this response is unknown.
The purpose of this project is to determine the acute effects of varying exercise intensities
on the time spent in a low blood sugar range in 10 sedentary (VIGOR acute sedentary) and 16
physically active (VIGOR acute trained) individuals with T1D. Each participant will complete
a maximal exercise test prior to the exercise sessions. Sedentary participants will complete
45 minutes of continuous moderate intensity exercise at 45-55% heart rate reserve (HRR) and
three high intensity interval sessions with six one minute burst of high intensity at 70%,
80%, or 90% of HRR every four minutes. Active participants will complete 45 minutes of
moderate intensity exercise at 45-55% of HRR and one high intensity interval session at 90%
of HRR with intervals spaced every two minutes.
The investigators will track the blood sugar response to exercise using a device called a
continuous glucose monitor (CGM) which records blood sugar every five minutes over a period
of six days. The CGM will help determine which exercise intensity does a better job at
reducing the time spent in a low blood sugar range. The information gained through this study
will help individuals with T1D remain active without fear of low blood sugar and provide
guidelines for professionals working with this population.
Adding high intensity bursts at 80% and 90% of maximum aerobic capacity (active participants)
or heart rate reserve (sedentary participants) to a moderate intensity exercise session will
significantly reduce the amount of time spent in a low blood sugar range in sedentary and
active persons with T1D compared to moderate intensity exercise alone.
Status | Completed |
Enrollment | 10 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 35 Years |
Eligibility |
Inclusion Criteria: - Persons with type 1 diabetes - Hemoglobin A1c <9.9% - Diabetes duration >/= 2 years - Sedentary Participants: participate in <150 minutes of moderate to vigorous physical activity per week - Active Participants: regular performance of vigorous physical activity >3 times/week for over one year. Display a maximal oxygen uptake that is at least 40.9 ml/kg/min for females, and 49.3 ml/kg/min for males. Exclusion Criteria: - HbA1c =9.9% as the lack of compliance with insulin suggests they may not be able to comply with the prescribed exercise requirements - Have frequent and unpredictable hypoglycemia as they will be at a greater risk of serious hypoglycemic events - Had a change in insulin management strategy, including adoption of a pump within two months of enrolment or switching back to multiple daily injections in the last two months, as they may be at risk for a hypoglycemic event due to the novel insulin management approach - Have conditions that would render vigorous intensity activity contraindicated including: uncontrolled hypertension: BP >150 mm Hg systolic or >95 mm Hg diastolic in a sitting position; severe peripheral neuropathy; or history of cardiovascular disease - Cognitive deficit resulting in an inability to provide informed consent - Are currently taking beta-blockers as this would limit the ability to achieve target heart rates within the prescribed range - Are currently being treated with medications (other than insulin) that alter glucose metabolism (i.e. atypical antipsychotics, corticosteroids) - Are women who are pregnant, breastfeeding, or planning to get pregnant - Have a job or profession that involves shift work (working during the night time, and being asleep during the daytime, as this alters glucose levels. |
Country | Name | City | State |
---|---|---|---|
Canada | Children's Hospital Research Institute of Manitoba | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
University of Manitoba | The Lawson Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cortisol | Cortisol levels are assessed to see if these values are protective against hypoglycemia. Measured by competitive immunoassay with biotinylated polyclonal antibody against cortisol. Sedentary group only. | two hours post exercise | |
Other | Growth hormone | Growth hormone levels are assessed to see if these values are protective against hypoglycemia. As measured by immunosorbent assay. Sedentary group only. | two hours post exercise | |
Other | Muscle mass as assessed by DEXA | For active individuals only. Muscle mass will be measured using a DEXA scanner | Baseline appointment ~20 minutes | |
Primary | Percent time spent </= 3.9 mmol/L as measured by continuous glucose monitor | The time spent = 3.9 mmol/L is measured through the continuous glucose monitor and is represented as a percentage. | 12 hours post exercise (6:00 PM to 6:00 AM) | |
Secondary | Mean absolute glucose change (MAG-mmol/L/h) as measured by continuous glucose monitor | Glucose variability will be measured using a continuous glucose monitor assessed through mean absolute glucose change (MAG) which is a measure of inter-day variability (mmol/L/h) | 12 hours post exercise (6:00 PM to 6:00 AM) | |
Secondary | Continuous overall net glycemic action (CONGA-mmol/L) as measured by continuous glucose monitor | CONGA will be measured using a continuous glucose monitor assessed through overall net glycemic action (CONGA) which is a measure of intra-day variability (mmol/L). | 12 hours post exercise (6:00 PM to 6:00 AM) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 | |
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |